PAX-8 (Paired box protein 8)

Product Code: PAX008-0.5

Code	Size	Price

PAX008-0.5

0.5 ml

£833.00

Quantity:

Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit

Antibody Isotype: IgG

Antibody Clonality: Monoclonal

Antibody Clone: ZR-1

Regulatory Status: RUO

Target Species: Human

Applications:

Immunohistochemistry- Frozen Section (IHC-F)
Immunohistochemistry- Paraffin Embedded (IHC-P)

Storage:

2-8°C

Documents

Further Information

Further Information

Applications Description:

IHC (C,P)

Background:

The antibody against PAX-8 is well suited for the detection of the protein in ovarian clear cell carcinoma. The cellular localization is nuclear. PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometroid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 expression in renal tubules as well as renal carcinoma, nephroblastoma and seminoma. Over 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of oncocytomas were positive for PAX-8, frequencies which are similar or better than for PAX-2. Normal lung and lung carcinomas do not express PAX-8. Similarly, the absence of expression of PAX-8 in breast and other non-GYN carcinomas other than those primary to the thyroid indicates that PAX-8 is an important new marker of ovarian cancer and a useful marker for the differential diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma or thyroid carcinoma are possibilities. PAX-8, combined with organ system-specific markers such as uroplakin, mammaglobin, and TTF-1 can be a very useful panel to differentiate the primary site of invasive micro-papillary carcinomas of ovary from those of the bladder, lung, and breast. PAX-8 protein.

Caution:

These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
The preservative sodium azide has been added in very small quantities. Nevertheless, it may be harmful to health and the reagent should be used only by trained personnel. For waste disposal, please refer to national regulations.

Immunogen:

Synthetic peptide corresponding to the C-terminus of Human PAX8 protein

Positive Control:

Thyroid carcinoma, Ovarian Clear Cell Carcinoma

Pre-Treatment:

Pre-treatment of dewaxed tissue with heat-induced epitope retrieval (TRIS/EDTA, pH9.0 Ref. DE006) is recommended.

Product:

Tissue culture supernatant with 0.2% BSA and 15 mM sodium azide

Purification Method:

Tissue culture supernatant with 0.2% BSA and 15 mM sodium azide

Source:

Rabbits were immunized with a synthetic peptide corresponding to the C-terminus of Human PAX8 protein.

Species Reactivity:

Human, others not known

Synonyms:

Paired box protein 8

UniProt:

Q06710 (PAX8_HUMAN)

Working Concentration:

(liquid conc.) 1:50-1:100

References

1. Poleev A., Fickenscher H., Mundlos S., Winterpacht A., Zabel B., Fidler A., Gruss P., Plachov D. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 116:611-623(1992) [PubMed: 1337742]
2. Kozmik Z., Kurzbauer R., Doerfler P., Busslinger M. "Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol. Cell. Biol. 13:6024-6035(1993) [PubMed: 8413205]
3. Vilain C., Rydlewski C., Duprez L., Heinrichs C., Abramowicz M., Malvaux P., Renneboog B., Parma J., Costagliola S., Vassart G. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J. Clin. Endocrin